These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11118091)

  • 1. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation.
    Legendre CM; Norman DJ; Keating MR; Maclaine GD; Grant DM
    Transplantation; 2000 Nov; 70(10):1463-8. PubMed ID: 11118091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.
    Mauskopf JA; Richter A; Annemans L; Maclaine G
    Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation.
    Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S
    Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic value of valacyclovir prophylaxis in transplantation.
    Squifflet JP; Legendre C
    J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lowering immunosuppression to treat CMV infection in renal transplant recipients on valaciclovir prophylaxis: a pilot study.
    Anglicheau D; Lautrette A; Scieux C; Flamant M; Morinet F; Legendre C
    Nephrol Dial Transplant; 2003 Aug; 18(8):1654-6. PubMed ID: 12897109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Feinberg JE; Hurwitz S; Cooper D; Sattler FR; MacGregor RR; Powderly W; Holland GN; Griffiths PD; Pollard RB; Youle M; Gill MJ; Holland FJ; Power ME; Owens S; Coakley D; Fry J; Jacobson MA
    J Infect Dis; 1998 Jan; 177(1):48-56. PubMed ID: 9419169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
    Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation.
    Legendre C; Beard SM; Crochard A; Lebranchu Y; Pouteil-Noble C; Richter A; Durand-Zaleski I
    Eur J Health Econ; 2005 Jun; 6(2):172-82. PubMed ID: 15765243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
    Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
    Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
    Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
    Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
    Ormrod D; Scott LJ; Perry CM
    Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.
    Egan JJ; Carroll KB; Yonan N; Woodcock A; Crisp A
    J Heart Lung Transplant; 2002 Apr; 21(4):460-6. PubMed ID: 11927223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
    Reischig T; Kacer M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering immunosuppression is safe and effective to treat altered pattern of CMV infection in renal transplant recipients on valaciclovir prophylaxis.
    Anglicheau D; Lautrette A; Scieux C; Thervet E; Martinez F; Flamant M; Morinet F; Legendre C
    Transplant Proc; 2002 Nov; 34(7):2826-7. PubMed ID: 12431624
    [No Abstract]   [Full Text] [Related]  

  • 18. CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir.
    Sund F; Wahlberg J; Eriksson BM
    J Clin Virol; 2001 Dec; 23(1-2):107-11. PubMed ID: 11595589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
    Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.